Erythropoietin, normally produced in the kidney and liver, is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. EPO is indicated for treatment of neutropenia or anemia secondary to ZDV- or Ganciclovir-induced bone marrow suppression (most effective in patients with endogenous EPO levels < 500 IU/ml).
Applications:
Suitable for use in ELISA. Other applications not tested.
Recommended Dilution:
Optimal dilutions to be determined by the researcher.
Hybridoma:
Sp2/0-Ag14 myeloma cells with spleen cells from Balb/c mice.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Reconstitute with sterile 40-50% glycerol, aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.